{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:27:50Z","timestamp":1793946470714,"version":"4.8.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004586","name":"Carlos Chagas Filho Foundation for Research Support of Rio de Janeiro State","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105455","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:42:01Z","timestamp":1782492121000},"page":"105455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Oral melanoma in the immunotherapy era: Immune evasion, resistance, and therapeutic opportunities"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6599-3950","authenticated-orcid":false,"given":"Jos\u00e9 Alcides Almeida","family":"de Arruda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Zanetti","family":"Drumond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhilde Callou","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 C\u00e2ndido Caldeira","family":"Xavier-J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo Castro","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarc\u00edlia Aparecida","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Augusto Benevenuto","family":"de Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105455_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/odi.70206","article-title":"Pembrolizumab with anlotinib in advanced oral mucosal melanoma: a retrospective trial","author":"Bi","year":"2026","journal-title":"Oral. Dis."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105455_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jcms.2025.01.012","article-title":"Clinical patterns and outcomes of patients affected by primary malignant melanoma of the oral mucosa: a European multicenter retrospective chart review","volume":"53","author":"Boffano","year":"2025","journal-title":"J. Craniomaxillofac Surg."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1902\/cap.2016.160003","article-title":"Primary oral melanoma - a non-surgical approach to treatment via immunotherapy","volume":"7","author":"Casta\u00f1o","year":"2017","journal-title":"Clin. Adv. Periodontics"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105455_bib4","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.bjoms.2020.05.028","article-title":"Survival of oral mucosal melanoma according to treatment, tumour resection margin, and metastases","volume":"58","author":"Chae","year":"2020","journal-title":"Br. J. Oral. Maxillofac. Surg."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105455_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.1611","article-title":"Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: a systematic review and network meta-analysis","volume":"3","author":"Chang","year":"2020","journal-title":"JAMA Netw. Open."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.oooo.2016.01.005","article-title":"Primary mucosal melanoma of the oral cavity: current therapy and future directions","volume":"122","author":"Chatzistefanou","year":"2016","journal-title":"Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol."},{"issue":"7718","key":"10.1016\/j.critrevonc.2026.105455_bib7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105455_bib8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D\u2019Angelo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105455_bib9","first-page":"1","article-title":"Data scarcity and the invisible burden of oral melanoma in Latin America: an urgent call to action","volume":"0","author":"de Arruda","year":"2026","journal-title":"Oral. Surg."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105455_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/pcmr.70017","article-title":"Oral melanoma in older adults: epidemiology, molecular landscape, and treatment strategies","volume":"38","author":"de Arruda","year":"2025","journal-title":"Pigment. Cell. Melanoma Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105455_bib11","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","article-title":"The 2018 World Health Organization Classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary Pathway","volume":"144","author":"Elder","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105455_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/vco.13039","article-title":"PD-L1, PD-1, and CTLA-4 mRNA in situ expression by canine oral melanoma cells and immune cells of the tumour microenvironment","volume":"23","author":"Foiani","year":"2025","journal-title":"Vet. Comp. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/1346-8138.14041","article-title":"Synergistic effects of interferon-beta and nivolumab in oral mucosal melanoma","volume":"45","author":"Fusumae","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.critrevonc.2026.105455_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","article-title":"PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: A systematic review and meta-analysis","volume":"100","author":"Gandini","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105455_bib15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/his.15562","article-title":"WHO classification of skin tumours: key updates in the fifth edition","volume":"88","author":"Goldman-L\u00e9vy","year":"2026","journal-title":"Histopathology"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105455_bib16","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.3390\/cancers17162648","article-title":"Confronting melanoma radioresistance: mechanisms and therapeutic strategies","volume":"17","author":"Gorodetska","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/hed.26470","article-title":"The effectiveness of radiotherapy in the treatment of head and neck mucosal melanoma: systematic review and meta-analysis","volume":"43","author":"Grant-Freemantle","year":"2021","journal-title":"Head. Neck"},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105455_bib18","first-page":"01498","article-title":"Hallmarks of cancer-then and now, and beyond","volume":"S0092-8674","author":"Hanahan","year":"2026","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105455_bib19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11912-024-01513-w","article-title":"Head and neck mucosal melanoma: where are we now?","volume":"26","author":"Hanba","year":"2024","journal-title":"Curr. Oncol. Rep."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105455_bib20","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3390\/cells14231884","article-title":"Mucosal melanoma: mechanisms of its etiology, progression, resistance and therapy","volume":"14","author":"Hassan","year":"2025","journal-title":"Cells"},{"issue":"7653","key":"10.1016\/j.critrevonc.2026.105455_bib21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105455_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmorc.2026.100134","article-title":"Initial experience with perioperative immune checkpoint inhibitors combined with radiotherapy for head and neck mucosal melanoma: a case series","author":"Hiraoka","year":"2026","journal-title":"ESMO Rare Cancers"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105455_bib23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105455_bib24","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3390\/vetsci12090850","article-title":"Exploratory, randomized, dose-response study of the anti-PD-L1 antibody HFC-L1\/c4G12 in dogs with pulmonary metastatic oral malignant melanoma","volume":"12","author":"Hosoya","year":"2025","journal-title":"Vet. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105455_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/DAD.0000000000000605","article-title":"Mutational status of NRAS and BRAF genes and protein expression analysis in a series of primary oral mucosal melanoma","volume":"39","author":"Hsieh","year":"2017","journal-title":"Am. J. Dermatopathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/imr.70071","article-title":"Dendritic cell organization and function in innate and adaptive immune defense within lymph nodes","volume":"337","author":"Huang","year":"2026","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2026.105455_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106807","article-title":"Mutational landscape of oral mucosal melanoma based on comprehensive cancer genomic profiling tests in a Japanese cohort","volume":"152","author":"Ichimura","year":"2024","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105455_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104919","article-title":"Abscopal effect of radiation therapy after nivolumab monotherapy in a patient with oral mucosal melanoma: a case report","volume":"108","author":"Igarashi","year":"2020","journal-title":"Oral. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013623","article-title":"Caninized PD-1 monoclonal antibody in oral malignant melanoma: efficacy and exploratory biomarker analysis","volume":"14","author":"Igase","year":"2026","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105455_bib30","first-page":"673","article-title":"Experimental models for rare melanoma research-the niche that needs to be addressed","volume":"10","author":"Ionita","year":"2023","journal-title":"Bioeng. (Basel)"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105455_bib31","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105455_bib32","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/scd.12887","article-title":"Lesions in the oral mucosa associated with the use of checkpoint inhibitors: a bibliometric and critical review","volume":"44","author":"Jural","year":"2024","journal-title":"Spec. Care Dent."},{"key":"10.1016\/j.critrevonc.2026.105455_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/vco.70052","article-title":"Prognostic significance of tumour infiltrating lymphocytes in canine oral malignant melanoma treated with anti-programmed cell death ligand 1 (PD-L1) antibody therapy","author":"Kamo","year":"2026","journal-title":"Vet. Comp. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105455_bib34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CJI.0000000000000282","article-title":"Combination nivolumab\/ipilimumab immunotherapy for melanoma with subsequent unexpected cardiac arrest: a case report and review of literature","volume":"42","author":"Khoury","year":"2019","journal-title":"J. Immunother."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105455_bib35","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ijrobp.2006.01.016","article-title":"Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network study","volume":"65","author":"Krengli","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib36","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","article-title":"Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma","volume":"8","author":"Lauss","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib37","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1038\/s41467-024-47425-y","article-title":"Molecular patterns of resistance to immune checkpoint blockade in melanoma","volume":"15","author":"Lauss","year":"2024","journal-title":"Nat. Commun."},{"issue":"5256","key":"10.1016\/j.critrevonc.2026.105455_bib38","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105455_bib39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-0042-1750178","article-title":"International multicenter study of clinical outcomes of sinonasal melanoma shows survival benefit for patients treated with immune checkpoint inhibitors and potential improvements to the current TNM staging system","volume":"84","author":"Lechner","year":"2022","journal-title":"J. Neurol. Surg. B Skull Base"},{"key":"10.1016\/j.critrevonc.2026.105455_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155468","article-title":"Expression of immune checkpoint molecules TIGIT and TIM-3 by tumor-infiltrating lymphocytes predicts poor outcome in sinonasal mucosal melanoma","volume":"260","author":"Ledderose","year":"2024","journal-title":"Pathol. Res. Pract."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105455_bib41","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/lary.29820","article-title":"Prognostic value of tumor-infiltrating lymphocytes in sinonasal mucosal melanoma","volume":"132","author":"Ledderose","year":"2022","journal-title":"Laryngoscope"},{"key":"10.1016\/j.critrevonc.2026.105455_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920922028","article-title":"Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review","volume":"12","author":"Li","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105455_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2025.107267","article-title":"Efficacy of pembrolizumab monotherapy for advanced gingival malignant melanoma: a case report","volume":"164","author":"Li","year":"2025","journal-title":"Oral. Oncol."},{"issue":"47","key":"10.1016\/j.critrevonc.2026.105455_bib44","doi-asserted-by":"crossref","first-page":"82661","DOI":"10.18632\/oncotarget.19746","article-title":"The clinical significance of c-Kit mutations in metastatic oral mucosal melanoma in China","volume":"8","author":"Ma","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib45","doi-asserted-by":"crossref","first-page":"9265","DOI":"10.1038\/s41598-022-13484-8","article-title":"Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy","volume":"12","author":"Maekawa","year":"2022","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105455_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157176","article-title":"Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma","volume":"11","author":"Maekawa","year":"2016","journal-title":"PLoS. One"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib47","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1038\/s41598-017-09444-2","article-title":"A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma","volume":"7","author":"Maekawa","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105455_bib48","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/08830185.2020.1869732","article-title":"HLA-G expression in melanomas","volume":"40","author":"Marletta","year":"2021","journal-title":"Int. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105455_bib49","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jdermsci.2020.01.001","article-title":"Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma","volume":"97","author":"Mikoshiba","year":"2020","journal-title":"J. Dermatol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105455_bib50","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.it.2017.08.005","article-title":"Tissue-Specific Immunity at the Oral Mucosal Barrier","volume":"39","author":"Moutsopoulos","year":"2018","journal-title":"Trends Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105455_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100325","article-title":"Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)","volume":"6","author":"Nakamura","year":"2021","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105455_bib52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semcancer.2019.09.013","article-title":"The mutational landscape of mucosal melanoma","volume":"61","author":"Nassar","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib53","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","article-title":"Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets","volume":"10","author":"Newell","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib54","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pathol.2016.09.065","article-title":"BRAF, NRAS, KIT, TERT, GNAQ\/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases","volume":"49","author":"\u00d6zt\u00fcrk Sari","year":"2017","journal-title":"Pathology"},{"key":"10.1016\/j.critrevonc.2026.105455_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.890546","article-title":"Case report: good cardiac tolerance to toripalimab in a CVD patient with oral melanoma","volume":"13","author":"Pan","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib56","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1038\/s41467-020-18570-x","article-title":"PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade","volume":"11","author":"Peng","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105455_bib57","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/cells15030298","article-title":"mRNA vaccines in melanoma immunotherapy-a narrative review","volume":"15","author":"Plewa","year":"2026","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105455_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.105053","article-title":"BRAFV600E mutation in oral melanocytic nevus and oral mucosal melanoma","volume":"114","author":"Resende","year":"2021","journal-title":"Oral. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105455_bib59","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/his.15456","article-title":"Unveiling the molecular landscape and clinically relevant molecular heterogeneity of mucosal melanoma of the head and neck region","volume":"87","author":"Ricci","year":"2025","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2026.105455_bib60","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-026-04486-2","article-title":"Mucosal melanoma of the head and neck region: clinical-pathologic implications of tumor microenvironment evaluated with multiplex immunohistochemistry","author":"Ricci","year":"2026","journal-title":"Virchows Arch."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105455_bib61","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3390\/cancers15051356","article-title":"Current trends in mucosal melanomas: an overview","volume":"15","author":"Santeufemia","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105455_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001219","article-title":"Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission","volume":"9","author":"Satish","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105455_bib63","article-title":"Prognostic predictors of oral mucosal melanoma-a systematic review and meta-analysis","author":"Sebastian","year":"2025","journal-title":"Oral. Dis."},{"key":"10.1016\/j.critrevonc.2026.105455_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1441410","article-title":"Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes","volume":"15","author":"Shan","year":"2024","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105455_bib65","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.3390\/cancers15082206","article-title":"Dendritic cell subsets in melanoma: pathophysiology, clinical prognosis and therapeutic exploitation","volume":"15","author":"Sosa Cuevas","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7559","key":"10.1016\/j.critrevonc.2026.105455_bib66","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"issue":"200","key":"10.1016\/j.critrevonc.2026.105455_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105455_bib68","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.oraloncology.2012.01.019","article-title":"Treatment and prognosis of oral mucosal melanoma","volume":"48","author":"Sun","year":"2012","journal-title":"Oral. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105455_bib69","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41419-023-05961-3","article-title":"TIGIT, a novel immune checkpoint therapy for melanoma","volume":"14","author":"Tang","year":"2023","journal-title":"Cell. Death Dis."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105455_bib70","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.3390\/jcm14196863","article-title":"Mucosal melanoma of the oral cavity: prognostic factors influencing patient survival outcomes","volume":"14","author":"Tarnawski","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2026.105455_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2022.803093","article-title":"Canine melanoma immunology and immunotherapy: relevance of translational research","volume":"9","author":"Tarone","year":"2022","journal-title":"Front. Vet. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib72","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105455_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102870","article-title":"Effectiveness of immune checkpoint inhibitors and other treatment modalities in patients with advanced mucosal melanomas: a systematic review and individual patient data meta-analysis","volume":"77","author":"Teo","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105455_bib74","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/pcmr.13104","article-title":"Prognostic biomarkers for survival in mucosal melanoma","volume":"36","author":"Thierauf","year":"2023","journal-title":"Pigment. Cell. Melanoma Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105455_bib75","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1016\/j.jormas.2022.02.002","article-title":"Oral mucosal melanoma - a systematic review","volume":"123","author":"Thuaire","year":"2022","journal-title":"J. Stomatol. Oral. Maxillofac. Surg."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105455_bib76","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105455_bib77","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-19-1409","article-title":"Overcoming genetically based resistance mechanisms to PD-1 blockade","volume":"10","author":"Torrejon","year":"2020","journal-title":"Cancer Discov."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105455_bib78","doi-asserted-by":"crossref","first-page":"17282","DOI":"10.3390\/ijms242417282","article-title":"Current status and molecular mechanisms of resistance to immunotherapy in oral malignant melanoma","volume":"24","author":"Usta","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105455_bib79","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179982","article-title":"Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma","volume":"9","author":"Vos","year":"2024","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105455_bib80","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aan3864","article-title":"PD-1 and CTLA4: Two checkpoints, one pathway?","volume":"2","author":"Walker","year":"2017","journal-title":"Sci. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105455_bib81","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.joms.2011.03.036","article-title":"Primary oral mucosal melanoma: advocate a wait-and-see policy in the clinically N0 patient","volume":"70","author":"Wang","year":"2012","journal-title":"J. Oral. Maxillofac. Surg."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib82","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"31","key":"10.1016\/j.critrevonc.2026.105455_bib83","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1200\/JCO.23.01448","article-title":"Outcomes with postrecurrence systemic therapy following adjuvant checkpoint inhibitor treatment for resected melanoma in CheckMate 238","volume":"42","author":"Weber","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105455_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.105023","article-title":"A melanoma patient obtained sustained survival benefit from anti-PD-1 therapy in spite of MDM2 amplification","volume":"113","author":"Wei","year":"2021","journal-title":"Oral. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105455_bib85","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105455_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-026-03350-z","article-title":"Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time?","author":"Woodford","year":"2026","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib87","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12967-019-1987-z","article-title":"Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy","volume":"17","author":"Xu","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105455_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218359","article-title":"Emerging biomarkers in melanoma: Bridging molecular discovery and precision oncology","volume":"645","author":"Xu","year":"2026","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105455_bib89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13073-022-01050-w","article-title":"Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response","volume":"14","author":"Zhang","year":"2022","journal-title":"Genome Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:38:21Z","timestamp":1793943501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":89,"alternative-id":["S1040842826003422"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105455","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral melanoma in the immunotherapy era: Immune evasion, resistance, and therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105455"}}